These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15882132)

  • 1. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
    Lane HY; Lee CC; Liu YC; Chang WH
    Pharmacogenomics; 2005 Mar; 6(2):139-49. PubMed ID: 15882132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
    Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N
    Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.
    Lane HY; Lee CC; Chang YC; Lu CT; Huang CH; Chang WH
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):461-70. PubMed ID: 15140279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.
    Ikeda M; Yamanouchi Y; Kinoshita Y; Kitajima T; Yoshimura R; Hashimoto S; O'Donovan MC; Nakamura J; Ozaki N; Iwata N
    Pharmacogenomics; 2008 Oct; 9(10):1437-43. PubMed ID: 18855532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.
    Peñas-Lledó EM; Dorado P; Cáceres MC; de la Rubia A; Llerena A
    Clin Chem Lab Med; 2007; 45(7):835-8. PubMed ID: 17617023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia.
    Alladi CG; RajKumar RP; Adithan S; Marie-Claire C; Bellivier F; Shewade DG
    Fundam Clin Pharmacol; 2019 Jun; 33(3):355-364. PubMed ID: 30332506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone-related weight gain: genetic and nongenetic predictors.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
    J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.
    Lane HY; Chang YC; Chiu CC; Chen ML; Hsieh MH; Chang WH
    Am J Psychiatry; 2002 Sep; 159(9):1593-5. PubMed ID: 12202283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.
    Kim B; Choi EY; Kim CY; Song K; Joo YH
    Hum Psychopharmacol; 2008 Jan; 23(1):61-7. PubMed ID: 17924589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.
    Kaur G; Gupta D; Chavan BS; Sinhmar V; Prasad R; Tripathi A; Garg PD; Gupta R; Khurana H; Gautam S; Margoob MA; Aneja J
    Asian J Psychiatr; 2017 Oct; 29():174-182. PubMed ID: 28692863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
    Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sugawara N; Fujii A; Kaneko S
    J Clin Psychopharmacol; 2011 Oct; 31(5):633-7. PubMed ID: 21869689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics.
    Hamdani N; Bonnière M; Adès J; Hamon M; Boni C; Gorwood P
    Neurosci Lett; 2005 Mar; 377(1):69-74. PubMed ID: 15722190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
    Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
    J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.
    Lencz T; Robinson DG; Xu K; Ekholm J; Sevy S; Gunduz-Bruce H; Woerner MG; Kane JM; Goldman D; Malhotra AK
    Am J Psychiatry; 2006 Mar; 163(3):529-31. PubMed ID: 16513877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.
    Mössner R; Schuhmacher A; Kühn KU; Cvetanovska G; Rujescu D; Zill P; Quednow BB; Rietschel M; Wölwer W; Gaebel W; Wagner M; Maier W
    Pharmacogenet Genomics; 2009 Jan; 19(1):91-4. PubMed ID: 18849890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.
    Maffioletti E; Valsecchi P; Minelli A; Magri C; Bonvicini C; Barlati S; Sacchetti E; Vita A; Gennarelli M
    Drug Dev Res; 2020 Sep; 81(6):754-761. PubMed ID: 32462699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.
    Wang L; Fang C; Zhang A; Du J; Yu L; Ma J; Feng G; Xing Q; He L
    J Psychopharmacol; 2008 Nov; 22(8):904-9. PubMed ID: 18308786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.
    Ma L; Zhang X; Xiang Q; Zhou S; Zhao N; Xie Q; Zhao X; Zhou Y; Cui Y
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):94-104. PubMed ID: 30103286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.
    Scharfetter J
    Pharmacogenomics; 2004 Sep; 5(6):691-8. PubMed ID: 15335289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
    Li HQ; Xu JY; Gao YY; Jin L
    Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.